A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation)

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

To evaluate the efficacy and safety of Kangfu Xiaoyan Suppository in the treatment of pelvic inflammatory diseases (dampness-heat accumulation syndrome) and its influence on the sequelae of pelvic inflammatory diseases, and to study the role of traditional Chinese medicine in reducing the use of antibiotics and the risk of clinical medication, taking levofloxacin + metronidazole as the control drug.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China Academy of Chinese Medical Sciences
• Collaborators: Beijing Obstetrics and Gynecology Hospital; Chengdu University of Traditional Chinese Medicine; First Affiliated Hospital of Heilongjiang University of Traditional Chinese; First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; Longhua Hospital; Peking Union Medical College Hospital; Peking University First Hospital; Shenzhen Maternal and Child Health Hospital; Third Hospital of Peking University; Xiyuan Hospital of China Academy of Chinese Medical Sciences
• Treatments: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibiotics, Antitubercular

Criteria

Inclusion Criteria:

• (1) Women aged 20-50;

• (2) Sexual History ;

• (3) According to the diagnostic criteria of pelvic inflammatory diseases: according to the Diagnosis and Treatment Criteria of Pelvic Inflammatory Diseases (2014), the following specifications are as follows: A. uterine tenderness, or adnexal tenderness, or cervical lifting pain; B. axillary body temperature < 38 C. blood routine white blood cell count < 1.1 times the upper limit of normal value; D. blood routine neutrophil percentage < 90%;

All of the above four items are available. Exclusion Criteria:

• (4)McCormack:4-12;

• (5)TCM syndrome differentiation for damp-heat stagnation and Qi deficiency syndrome, A. lower abdominal pain; B. excessive amount of belt, yellow color, or odor; C. fatigue; D. tongue red, greasy fur, or with teeth marks, or blood stasis spots; the above four items are all available;

• (6)Those who agree to participate in this clinical trial and sign the informed consent form.

Exclusion Criteria:

• (1) Pregnant or recent (within 6 months) pregnant women, lactating women ;

• (2) To identify the pathogen as Neisseria gonorrhoeae;

• (3) Symptoms related to appendicitis, ectopic pregnancy, torsion or rupture of ovarian cyst pedicle, gastroenteritis, endometriosis, adenomyosis, trichomonal vaginitis, vulvovaginal candidiasis, bacterial vaginosis, etc.;

• (4)Those with critical condition or surgical indications, such as fallopian tube and ovary abscess, pelvic abscess, diffuse peritonitis, septicemia;

• (5)In patients with severe primary diseases such as heart, brain and hematopoietic system, ALT of liver function is higher than the upper limit of normal value, and Cr of renal function is higher than the upper limit of normal value;

• (6)One month before admission, Chinese and Western medicines were used to treat the disease, which made it difficult to judge the efficacy of drugs;

• (7)Anaphylactic constitution or persons known to be allergic to the medicines and their components used in this test ;

• (8)Researchers do not consider it appropriate to participate in this clinical trial;

• (9)Suspected or true history of alcohol and drug abuse, or other pathological changes or conditions that reduce the likelihood of enrollment or complicate enrollment, such as frequent changes in the working environment, unstable living environment, etc., are liable to lead to lost interviews, according to the judgement of researchers;

• (10)Participation in other clinical researchers within 3 months before admission;

• (11)Patients with suspected or confirmed quinolone contraindications, central or peripheral neuropathy, epilepsy, and depression